161 related articles for article (PubMed ID: 37692703)
1. FIP1L1-PDGFRA Clonal Hypereosinophilic Syndrome With Eosinophilic Myocarditis and Intracardiac Thrombus.
Locke M; Suen RM; Williamson AK; Nieto MJ
Cureus; 2023 Aug; 15(8):e43138. PubMed ID: 37692703
[TBL] [Abstract][Full Text] [Related]
2. Angioimmunoblastic T-cell lymphoma and hypereosinophilic syndrome with FIP1L1/PDGFRA fusion gene effectively treated with imatinib: A case report.
Yamamoto M; Ikuta K; Toki Y; Hatayama M; Shindo M; Torimoto Y; Okumura T
Medicine (Baltimore); 2017 Sep; 96(36):e8001. PubMed ID: 28885361
[TBL] [Abstract][Full Text] [Related]
3. Successful imatinib treatment of cardiac involvement of FIP1L1-PDGFRA-positive chronic eosinophilic leukemia followed by severe hepatotoxicity.
Arai A; Yan W; Wakabayashi S; Hayashi S; Inazawa J; Miura O
Int J Hematol; 2007 Oct; 86(3):233-7. PubMed ID: 17988989
[TBL] [Abstract][Full Text] [Related]
4. Case Report: Multimodal Imaging Guides the Management of an Eosinophilic Leukemia Patient With Eosinophilic Myocarditis and Intracardiac Thrombus.
Si J; Zhang X; Chen N; Sun F; Du P; Li Z; Tian D; Sun X; Sun G; Cong T; Du X; Liu Y
Front Cardiovasc Med; 2022; 9():903323. PubMed ID: 35722086
[TBL] [Abstract][Full Text] [Related]
5. CHIC2 deletion, a surrogate for FIP1L1-PDGFRA fusion, occurs in systemic mastocytosis associated with eosinophilia and predicts response to imatinib mesylate therapy.
Pardanani A; Ketterling RP; Brockman SR; Flynn HC; Paternoster SF; Shearer BM; Reeder TL; Li CY; Cross NC; Cools J; Gilliland DG; Dewald GW; Tefferi A
Blood; 2003 Nov; 102(9):3093-6. PubMed ID: 12842979
[TBL] [Abstract][Full Text] [Related]
6. [FIP1L1::PDGFRA-positive chronic eosinophilic leukemia showing slowly progressive cardiac impairment].
Shimizu M; Kuroda A; Suyama T; Seki M; Shinagawa A
Rinsho Ketsueki; 2022; 63(12):1648-1652. PubMed ID: 36653138
[TBL] [Abstract][Full Text] [Related]
7. FIP1L1-PDGFRA-Positive Chronic Eosinophilic Leukemia: A Low-Burden Disease with Dramatic Response to Imatinib - A Report of 5 Cases from South India.
Kumar AN; Sathyanarayanan V; Devi VL; Rajkumar NN; Das U; Dutt S; Chinnagiriyappa LK
Turk J Haematol; 2014 Mar; 31(1):56-60. PubMed ID: 24764730
[TBL] [Abstract][Full Text] [Related]
8. FIP1L1-PDGFRA fusion: prevalence and clinicopathologic correlates in 89 consecutive patients with moderate to severe eosinophilia.
Pardanani A; Brockman SR; Paternoster SF; Flynn HC; Ketterling RP; Lasho TL; Ho CL; Li CY; Dewald GW; Tefferi A
Blood; 2004 Nov; 104(10):3038-45. PubMed ID: 15284118
[TBL] [Abstract][Full Text] [Related]
9. Current concepts on the pathogenesis of the hypereosinophilic syndrome/chronic eosinophilic leukemia.
Yamada Y; Rothenberg ME; Cancelas JA
Transl Oncogenomics; 2006; 1():53-63. PubMed ID: 23662039
[TBL] [Abstract][Full Text] [Related]
10. Hypereosinophilic syndrome: endomyocardial biopsy versus echocardiography to diagnose cardiac involvement.
Butterfield JH; Kane GC; Weiler CR
Postgrad Med; 2017 Jun; 129(5):517-523. PubMed ID: 28440714
[TBL] [Abstract][Full Text] [Related]
11. The FIP1L1-PDGFRalpha kinase in hypereosinophilic syndrome and chronic eosinophilic leukemia.
Cools J; Stover EH; Wlodarska I; Marynen P; Gilliland DG
Curr Opin Hematol; 2004 Jan; 11(1):51-7. PubMed ID: 14676627
[TBL] [Abstract][Full Text] [Related]
12. Hypereosinophilic Syndrome, Multiorgan Involvement and Response to Imatinib.
Hana CK; Caldera H
Cureus; 2020 Jun; 12(6):e8493. PubMed ID: 32656011
[TBL] [Abstract][Full Text] [Related]
13. [Sustained hematologic response in chronic eosinophilic leukemia with low dose imatinib. Report of one case].
Torres C D; Chandía M
Rev Med Chil; 2014 Apr; 142(4):516-20. PubMed ID: 25117044
[TBL] [Abstract][Full Text] [Related]
14. Response to imatinib mesylate in patients with hypereosinophilic syndrome.
Arefi M; García JL; Briz MM; de Arriba F; Rodríguez JN; Martín-Núñez G; Martínez J; López J; Suárez JG; Moreno MJ; Merino MA; Gutiérrez NC; Hernández-Rivas JM
Int J Hematol; 2012 Sep; 96(3):320-6. PubMed ID: 22806436
[TBL] [Abstract][Full Text] [Related]
15. Ascites in a young male: idiopathic FIP1L1-PDGFRA-negative hypereosinophilic syndrome.
Kasinathan G; Sathar J
JRSM Open; 2020 Jan; 11(1):2054270419894826. PubMed ID: 32002188
[TBL] [Abstract][Full Text] [Related]
16. Myeloid neoplasm with eosinophilia associated with isolated extramedullary FIP1L1/PDGFRA rearrangement.
Hilal T; Fauble V; Ketterling RP; Kelemen K
Cancer Genet; 2018 Jan; 220():13-18. PubMed ID: 29310833
[TBL] [Abstract][Full Text] [Related]
17. Relapse following discontinuation of imatinib mesylate therapy for FIP1L1/PDGFRA-positive chronic eosinophilic leukemia: implications for optimal dosing.
Klion AD; Robyn J; Maric I; Fu W; Schmid L; Lemery S; Noel P; Law MA; Hartsell M; Talar-Williams C; Fay MP; Dunbar CE; Nutman TB
Blood; 2007 Nov; 110(10):3552-6. PubMed ID: 17709602
[TBL] [Abstract][Full Text] [Related]
18. Detection of the FIP1L1-PDGFRA fusion in idiopathic hypereosinophilic syndrome and chronic eosinophilic leukemia.
Cools J; Stover EH; Gilliland DG
Methods Mol Med; 2006; 125():177-87. PubMed ID: 16502585
[TBL] [Abstract][Full Text] [Related]
19. FIP1L1-PDGFRA-Associated Hypereosinophilic Syndrome as a Treatable Cause of Watershed Infarction.
Tennenbaum J; Groh M; Venditti L; Campos-Gazeau F; Chalayer E; De Broucker T; Hamidou M; Hunault M; Lyoubi A; Meunier R; Muron T; Sène D; Slama B; Guidoux C; Lefèvre G; Kahn JE; Denier C; Rohmer J
Stroke; 2021 Oct; 52(10):e605-e609. PubMed ID: 34304603
[TBL] [Abstract][Full Text] [Related]
20. Clinical and molecular features of FIP1L1-PDFGRA (+) chronic eosinophilic leukemias.
Vandenberghe P; Wlodarska I; Michaux L; Zachée P; Boogaerts M; Vanstraelen D; Herregods MC; Van Hoof A; Selleslag D; Roufosse F; Maerevoet M; Verhoef G; Cools J; Gilliland DG; Hagemeijer A; Marynen P
Leukemia; 2004 Apr; 18(4):734-42. PubMed ID: 14973504
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
